Craig Hallum Boosts Cellebrite DI (NASDAQ:CLBT) Price Target to $16.00

Cellebrite DI (NASDAQ:CLBTFree Report) had its price target raised by Craig Hallum from $14.00 to $16.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts also recently issued reports on the stock. William Blair raised shares of Cellebrite DI from a market perform rating to an outperform rating in a research note on Wednesday, March 13th. Bank of America upped their price target on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a buy rating in a research report on Monday. Finally, Needham & Company LLC upped their price target on shares of Cellebrite DI from $13.00 to $13.50 and gave the stock a buy rating in a research report on Thursday, March 28th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has an average rating of Buy and a consensus target price of $12.30.

Check Out Our Latest Report on Cellebrite DI

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $11.09 on Monday. Cellebrite DI has a 12-month low of $5.22 and a 12-month high of $12.50. The company has a market capitalization of $2.28 billion, a PE ratio of -25.79, a price-to-earnings-growth ratio of 1.94 and a beta of 1.53. The firm’s 50-day moving average is $10.87 and its two-hundred day moving average is $8.93.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. The business had revenue of $93.01 million for the quarter, compared to the consensus estimate of $85.43 million. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. On average, analysts forecast that Cellebrite DI will post 0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Large investors have recently made changes to their positions in the business. Virtus Fund Advisers LLC acquired a new stake in shares of Cellebrite DI in the fourth quarter worth $28,000. Parallel Advisors LLC increased its position in shares of Cellebrite DI by 75.0% in the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock worth $30,000 after acquiring an additional 1,500 shares in the last quarter. Quarry LP acquired a new stake in shares of Cellebrite DI in the fourth quarter worth $36,000. UBS Group AG acquired a new stake in shares of Cellebrite DI in the first quarter worth $26,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Cellebrite DI in the fourth quarter worth $46,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

Further Reading

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.